ERN1 and breast carcinoma: In this study, we confirmed that 4μ8C and MKC8866, two highly selective IRE1α RNase inhibitors, significantly reduced XBP1s level and suppressed the cell proliferation and cell cycle progression in HR+/HER2− breast cancer.